Common Stock and Stockholders' Equity (Deficit) | 9. Common Stock and Stockholders' Equity (Deficit) Common Stock Reserved for Future Issuance The Company reserved shares of common stock for future issuance as follows: As of April 30, 2022 January 31, 2022 Options outstanding 11,519,072 12,381,134 Restricted stock units outstanding 13,126,707 10,406,294 Remaining shares available for future issuance under the 2021 Plan 23,269,500 17,560,879 2021 Employee Stock Purchase Plan 3,721,613 1,900,000 Total 51,636,892 42,248,307 A to tal of 23,269,500 shares of the Company’s Class A common stock have been reserved for future issuance under the 2021 Plan. Stock Options The following table summarizes stock option activity for the 2021 Plans (aggregate intrinsic value in thousands): Options Outstanding Number of Options Outstanding Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (in Years) Aggregate Intrinsic Value Balance as of January 31, 2022 12,381,134 $ 1.93 5.7 $ 798,374 Stock options exercised ( 838,725 ) $ 0.59 $ 34,832 Stock options cancelled/forfeited/expired ( 23,337 ) $ 5.87 Balance as of April 30, 2022 11,519,072 $ 2.02 5.5 $ 519,181 Exercisable as of April 30, 2022 10,140,530 $ 1.55 5.3 $ 461,577 No options were granted during the three months ended April 30, 2022. Exercisable shares consist of 10,137,530 shares that are vested and 3,000 shares with an early exercise provision that are unvested as of April 30, 2022. The total grant-date fair value of stock options vested was $ 1.3 million and $ 1.8 million during the three months ended April 30, 2022 and 2021, respectively. The total intrinsic value of options exercised during the three months ended April 30, 2022 and 2021 were $ 34.8 million and $ 26.9 million, respectively. Restricted Stock Units The Company’s summary of restricted stock units ("RSUs"), activity under the 2014 Plan and the 2021 Plan is as follows: Number of Awards Weighted-Average Grant Date Fair Value Outstanding and unvested at January 31, 2022 10,406,294 $ 37.46 RSUs granted 3,676,379 $ 50.12 RSUs released ( 710,165 ) $ 24.64 RSUs cancelled ( 245,801 ) $ 33.64 Outstanding and unvested at April 30, 2022 13,126,707 $ 41.77 The total grant-date fair value of RSUs vested was $ 17.5 million during the three months ended April 30, 2022. There were no RSUs released during the three months ended April 30, 2021 as the Company was private and the performance condition for these RSUs was not met during the three months ended April 30, 2021. Employee Stock Purchase Plan In December 2021, the Company adopted the 2021 Employee Stock Purchase Plan (“ESPP”), which became effective upon completion of the IPO. A total of 3,721,613 shares of Class A common stock are available for sale under the ESPP. For the three months ended April 30, 2022, the Company recognized $ 3.1 million of stock-based compensation expense related to the ESPP. As of April 30, 2022, unreco gnized stock-based compensation expense related to the ESPP was approximatel y $ 17.5 million, which is expected to be recognized over a weighted-average period of approximatel y 1.6 years. Stock-Based Compensation Expense Total stock-based compensation expense recognized in the Company’s condensed consolidated statements of operations is as follows (in thousands): Three Months Ended April 30, 2022 2021 Cost of license $ - $ - Cost of support 1,959 106 Cost of cloud-hosted services 640 3 Cost of professional services 728 12 Sales and marketing 14,393 692 Research and development 14,738 423 General and administrative 13,801 490 Stock-based compensation expense, net of amounts capitalized $ 46,259 $ 1,726 Capitalized stock-based compensation 882 - Total stock-based compensation expense $ 47,141 $ 1,726 As of April 30, 2022, total unrecognized stock-based compensation expense related to unvested stock options and RSUs was approximately $ 4.0 million and $ 420.6 million, respectively. This unrecognized stock-based compensation expense is expected to be recognized over a weighted-average period of approximately 1.5 and 3.1 years, respectively. |